Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2020
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia – Pipeline Review, H1 2020, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.
Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 86, 80, 7, 8, 86, 12 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 34, 28, 28, 2 and 1 molecules, respectively.
Acute Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia – Pipeline Review, H1 2020, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.
Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 86, 80, 7, 8, 86, 12 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 34, 28, 28, 2 and 1 molecules, respectively.
Acute Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
Appendix
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..6), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H1 2020
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc, H1 2020
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ADC Therapeutics SA, H1 2020
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..6), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H1 2020
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc, H1 2020
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ADC Therapeutics SA, H1 2020
LIST OF FIGURES
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
4SC AG
AbbVie Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Aeglea BioTherapeutics Inc
Aileron Therapeutics Inc
AIMM Therapeutics BV
Aleta Biotherapeutics Inc
Allterum Therapeutics LLC
Amgen Inc
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
Apexian Pharmaceuticals Inc
Applied Therapeutics Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
AUM Biosciences Pte Ltd
Autolus Therapeutics Plc
Avalon GloboCare Corp
AVM Biotechnology LLC
Ayala Pharmaceuticals Inc
Beam Therapeutics Inc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
Bioceltech Therapeutics Ltd
Biocure Technology Inc
BioSight Ltd
Bristol-Myers Squibb Co
Cambridge Innovation Technologies Consulting Ltd
CanBas Co Ltd
CARsgen Therapeutics Ltd
CASI Pharmaceuticals Inc
Cellectis SA
Cellestia Biotech AG
Cellipse SAS
Cellular Biomedicine Group Inc
Celularity Inc
China Immunotech Co Ltd
CoImmune Inc
CRISPR Therapeutics AG
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals Inc
Delta-Fly Pharma Inc
DevaCell Inc
Dialectic Therapeutics Inc
Diazon Pharmaceuticals Inc
DiNonA Inc
Elf Zone Inc
Eli Lilly and Co
Enzyme by Design Inc
Epizyme Inc
ERYTECH Pharma SA
Eureka Therapeutics Inc
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Felicitex Therapeutics Inc
Fusion Pharma LLC
Gamida Cell Ltd
Gansu Provincial Cancer Hospital
GEMoaB Monoclonals GmbH
Generium
Generon (Shanghai) Corp Ltd
Genexine Inc
Gilead Sciences Inc
Gracell Biotechnology Ltd
GT Biopharma Inc
Guangzhou Bio-gene Technology Co Ltd
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HemoGenyx LLC
HighPass Bio Inc
Hillstream BioPharma Inc
Housey Pharmaceutical Research Laboratories LLC
HRAIN Biotechnology Co Ltd
Humanigen Inc
Hummingbird Bioscience Pte Ltd
Hunan Siweikang Therapeutics Ltd
iCell Gene Therapeutics LLC
iDD biotech SAS
Iksuda Therapeutics Ltd
ImCheck Therapeutics SAS
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunityBio Inc
ImmunoGen Inc
Immunomedics Inc
Immunotech Biopharm Ltd
Inatherys
Incuron LLC
Incysus Therapeutics Inc
Incyte Corp
Innovative Cellular Therapeutics Co Ltd
Interprotein Corp
Jazz Pharmaceuticals Plc
Johnson & Johnson
Juno Therapeutics Inc
Juventas Cell Therapy Ltd
Karyopharm Therapeutics Inc
Kecellitics Biotech Co Ltd
Kiromic BioPharma Inc
Kronos Bio Inc
Kuur Therapeutics Ltd
LegoChem Biosciences Inc
Les Laboratoires Servier SAS
Light Chain Bioscience
Lin Bioscience Inc
MAA Laboratories Inc
MacroGenics Inc
Magenta Therapeutics Inc
MannKind Corp
Marker Therapeutics Inc
Medivir AB
Merck & Co Inc
Meryx Inc
Millennium Pharmaceuticals Inc
Miltenyi Biotec GmbH
Molecular Templates Inc
Nanjing Bioheng Biotech Co Ltd
Nanjing Iaso Biotherapeutics Co Ltd
Nanjing KAEDI Biotech Inc
Nanjing Legend Biotech Co Ltd
Nanovalent Pharmaceuticals Inc
NantKwest Inc
Nimbus Therapeutics LLC
Nkarta Inc
Nohla Therapeutics Inc
Novartis AG
NovoMedix LLC
Omeros Corp
Oncoceutics Inc
Onconova Therapeutics Inc
OncoTartis Inc
OncoTherapy Science Inc
Orca Biosystems Inc
OSE Immunotherapeutics
Pascal Biosciences Inc
PentixaPharm GmbH
PeproMene Bio Inc
PersonGen Biomedicine Suzhou Co Ltd
Pfenex Inc
Pfizer Inc
Pharma Mar SA
PharmaEssentia Corp
Precision Biosciences Inc
Protheragen Inc
PTC Therapeutics Inc
Regenacy Pharmaceuticals LLC
Regeneron Pharmaceuticals Inc
Retrotherapy LLC
Ryvu Therapeutics SA
Samus Therapeutics LLC
Sanofi
Sareum Holdings Plc
SciTech Development LLC
SELLAS Life Sciences Group Inc
Shanghai Bioray Laboratory Inc
Shanghai GeneChem Co Ltd
Shanghai Longyao Biotechnology Inc Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Inc
Shenzhen BinDeBio Ltd
Sian Wuhan Medical Technology Co Ltd
SpecificiT Pharma Inc
Spectrum Pharmaceuticals Inc
AIkido Pharma Inc
Sun Pharma Advanced Research Company Ltd
Sunnycell Therapeutics Ltd
SunRock Biopharma SL
Syndax Pharmaceuticals Inc
SYNIMMUNE GmbH
Tacitus Therapeutics Inc
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
TC BioPharm Ltd
TCR2 Therapeutics Inc
TheraPharm Deutschland GmbH
Tianjin Mycure Medical Technology Co Ltd
Tolero Pharmaceuticals Inc
Trillium Therapeutics Inc
Triphase Accelerator Corp
UWELL Biopharma Inc
VelosBio Inc
Vor BioPharma Inc
Wugen Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xbrane Biopharma AB
Xencor Inc
Zhejiang Teruisi Pharmaceutical Inc
Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd
ZIOPHARM Oncology Inc
Zovis Pharmaceuticals
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
4SC AG
AbbVie Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Aeglea BioTherapeutics Inc
Aileron Therapeutics Inc
AIMM Therapeutics BV
Aleta Biotherapeutics Inc
Allterum Therapeutics LLC
Amgen Inc
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
Apexian Pharmaceuticals Inc
Applied Therapeutics Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
AUM Biosciences Pte Ltd
Autolus Therapeutics Plc
Avalon GloboCare Corp
AVM Biotechnology LLC
Ayala Pharmaceuticals Inc
Beam Therapeutics Inc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
Bioceltech Therapeutics Ltd
Biocure Technology Inc
BioSight Ltd
Bristol-Myers Squibb Co
Cambridge Innovation Technologies Consulting Ltd
CanBas Co Ltd
CARsgen Therapeutics Ltd
CASI Pharmaceuticals Inc
Cellectis SA
Cellestia Biotech AG
Cellipse SAS
Cellular Biomedicine Group Inc
Celularity Inc
China Immunotech Co Ltd
CoImmune Inc
CRISPR Therapeutics AG
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals Inc
Delta-Fly Pharma Inc
DevaCell Inc
Dialectic Therapeutics Inc
Diazon Pharmaceuticals Inc
DiNonA Inc
Elf Zone Inc
Eli Lilly and Co
Enzyme by Design Inc
Epizyme Inc
ERYTECH Pharma SA
Eureka Therapeutics Inc
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Felicitex Therapeutics Inc
Fusion Pharma LLC
Gamida Cell Ltd
Gansu Provincial Cancer Hospital
GEMoaB Monoclonals GmbH
Generium
Generon (Shanghai) Corp Ltd
Genexine Inc
Gilead Sciences Inc
Gracell Biotechnology Ltd
GT Biopharma Inc
Guangzhou Bio-gene Technology Co Ltd
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HemoGenyx LLC
HighPass Bio Inc
Hillstream BioPharma Inc
Housey Pharmaceutical Research Laboratories LLC
HRAIN Biotechnology Co Ltd
Humanigen Inc
Hummingbird Bioscience Pte Ltd
Hunan Siweikang Therapeutics Ltd
iCell Gene Therapeutics LLC
iDD biotech SAS
Iksuda Therapeutics Ltd
ImCheck Therapeutics SAS
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunityBio Inc
ImmunoGen Inc
Immunomedics Inc
Immunotech Biopharm Ltd
Inatherys
Incuron LLC
Incysus Therapeutics Inc
Incyte Corp
Innovative Cellular Therapeutics Co Ltd
Interprotein Corp
Jazz Pharmaceuticals Plc
Johnson & Johnson
Juno Therapeutics Inc
Juventas Cell Therapy Ltd
Karyopharm Therapeutics Inc
Kecellitics Biotech Co Ltd
Kiromic BioPharma Inc
Kronos Bio Inc
Kuur Therapeutics Ltd
LegoChem Biosciences Inc
Les Laboratoires Servier SAS
Light Chain Bioscience
Lin Bioscience Inc
MAA Laboratories Inc
MacroGenics Inc
Magenta Therapeutics Inc
MannKind Corp
Marker Therapeutics Inc
Medivir AB
Merck & Co Inc
Meryx Inc
Millennium Pharmaceuticals Inc
Miltenyi Biotec GmbH
Molecular Templates Inc
Nanjing Bioheng Biotech Co Ltd
Nanjing Iaso Biotherapeutics Co Ltd
Nanjing KAEDI Biotech Inc
Nanjing Legend Biotech Co Ltd
Nanovalent Pharmaceuticals Inc
NantKwest Inc
Nimbus Therapeutics LLC
Nkarta Inc
Nohla Therapeutics Inc
Novartis AG
NovoMedix LLC
Omeros Corp
Oncoceutics Inc
Onconova Therapeutics Inc
OncoTartis Inc
OncoTherapy Science Inc
Orca Biosystems Inc
OSE Immunotherapeutics
Pascal Biosciences Inc
PentixaPharm GmbH
PeproMene Bio Inc
PersonGen Biomedicine Suzhou Co Ltd
Pfenex Inc
Pfizer Inc
Pharma Mar SA
PharmaEssentia Corp
Precision Biosciences Inc
Protheragen Inc
PTC Therapeutics Inc
Regenacy Pharmaceuticals LLC
Regeneron Pharmaceuticals Inc
Retrotherapy LLC
Ryvu Therapeutics SA
Samus Therapeutics LLC
Sanofi
Sareum Holdings Plc
SciTech Development LLC
SELLAS Life Sciences Group Inc
Shanghai Bioray Laboratory Inc
Shanghai GeneChem Co Ltd
Shanghai Longyao Biotechnology Inc Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Inc
Shenzhen BinDeBio Ltd
Sian Wuhan Medical Technology Co Ltd
SpecificiT Pharma Inc
Spectrum Pharmaceuticals Inc
AIkido Pharma Inc
Sun Pharma Advanced Research Company Ltd
Sunnycell Therapeutics Ltd
SunRock Biopharma SL
Syndax Pharmaceuticals Inc
SYNIMMUNE GmbH
Tacitus Therapeutics Inc
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
TC BioPharm Ltd
TCR2 Therapeutics Inc
TheraPharm Deutschland GmbH
Tianjin Mycure Medical Technology Co Ltd
Tolero Pharmaceuticals Inc
Trillium Therapeutics Inc
Triphase Accelerator Corp
UWELL Biopharma Inc
VelosBio Inc
Vor BioPharma Inc
Wugen Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xbrane Biopharma AB
Xencor Inc
Zhejiang Teruisi Pharmaceutical Inc
Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd
ZIOPHARM Oncology Inc
Zovis Pharmaceuticals
